ABT: Q3 growth accelerated as a tax-free nutrition separation and 2027 growth push take shape

Abbott Laboratories reported Q3 2026 sales growth of 7%, driven by diagnostics and electrophysiology. The company plans to separate its nutrition business by late 2027, aiming for accelerated sales and margin growth. Q4 guidance includes a temporary headwind in the LAA market. Management expects continued growth in 2027, with new product launches. The nutrition spin-off is expected to be tax-free, with both entities maintaining strong capital positions.

Abbott plans to spin off its nutrition business, which has $8.5B annual sales, into a separate publicly traded company by late 2027. The move aims to focus on higher-growth markets. Abbott's Q3 revenue was $13.01B, with nutrition contributing $2.26B. The spinout is not expected to impact 2026-2027 guidance. Abbott faces ongoing litigation related to its nutrition business.

Abbott Laboratories (ABT) reported Q3 2026 earnings matching expectations, with revenue of $13.01B and adjusted EPS of $1.42. The stock fell 3.42% due to a guidance cut, trimming full-year sales growth to 6%. Diagnostics and nutrition sales grew, but electrophysiology and diabetes care slowed. Management plans to separate the nutrition business. Next catalysts include Libre Duo launch, payer formulary changes, and Q4 results.

Abbott Laboratories plans to separate its nutrition business, generating $8.5B in annual sales, into an independent company by late 2024. The move aims to focus Abbott on medical devices and diagnostics while allowing the nutrition unit to capitalize on global demand. Abbott shares fell 2.1% on Wednesday. The company reported lower Q3 profit due to higher costs, with adjusted earnings of $1.42 per share, meeting expectations.

Abbott Laboratories (ABT) plans to spin off its nutrition business, which includes brands like Similac and Pedialyte, by 2027. The new company is expected to have $8.5B in annual sales. Abbott's nutrition sales dropped 4.5% in the U.S. in 2026. The move follows years of legal challenges related to its infant formulas.

Abbott Laboratories reported Q3 2026 adjusted earnings of $1.42 per share, matching estimates, on revenue of $13.01 billion, slightly above forecasts. Sales rose 7% and adjusted EPS increased 9% year-over-year. The company cut full-year sales growth guidance to 6% and announced plans to spin off its nutrition business. Shares fell 2.69% in premarket trading.